Please login to the form below
myelofibrosis
This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.
FDA turns down Celgene’s filing for multiple sclerosis drug
$7bn for Impact Biomedicines to add late-stage candidate fedratinib for myelofibrosis and polycythemia vera.
Latest news
-
Is acquisitive Celgene now eyeing CAR-T specialist Juno?
inhibitor - fedratinib - in development for myelofibrosis and polycythaemia vera.
-
Celgene boosts haematology pipeline with $7bn Impact Bio deal
The US biotech is spending $1.1bn in upfront cash to buy Impact Bio and its late-stage drug candidate fedratinib, a JAK2 inhibitor in development for myelofibrosis and polycythaemia vera ... Fedratinib demonstrated clinical improvement in the phase III
-
J&J aiming for above-average growth thanks to stream of blockbusters
Also name-checked in the R&D update was imetelstat for myelofibrosis, which J&J is co-developing with Geron for a number of indications under a $934m deal agreed in
-
Another late-stage setback tarnishes Gilead's R&D lustre
Another late-stage setback tarnishes Gilead's R&D lustre. Myelofibrosis drug candidate fails to best Incyte/Novartis’ Jakafi in phase III trials. ... Jakafi cleared $1bn in sales last year as a treatment for myelofibrosis and another bone marrow
-
Incyte abandons solid tumour programme for Jakafi
Jakafi is already a successful product for Incyte in its approved indications of polycythemia vera and myelofibrosis, bringing in $182m in direct sales for the company in the fourth quarter as
More from news
Approximately 8 fully matching, plus 39 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Celgene will pay approximately $1.1bn upfront for Impact and further contingent payments based on regulatory approval for fedratinib in myelofibrosis and other indications could amount to $1.4bn. ... Acquisition company - remaining 90%. 9, 000. Impact
-
Pharma deals in August 2015
Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐ 2 protein for idiopathic pulmonary fibrosis and myelofibrosis.
-
Pharma deals during November 2014
Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal
-
NICE and ‘ultra orphans’
It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,
-
Pharma deals during November 2013
Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and certain solid tumours.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Boston Biomedical appoints commercial head
At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
THE OTHER SIDE OF...BLOOD CANCER
He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Scientific Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and benefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Group Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and bebefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Account Manager – Med Comms – London
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
- Senior Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Project Manager, Medical Communications, London
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Project Manager, Medical Communications, Oxford
-
Excellent Salary
Subscribe to our email news alerts
- BenevolentAI raises $115m to fund drug development
- Shire rebuffs Takeda bids, as Allergan bows out
- Abeona Therapeutics names CEO
- Zelluna Immunotherapy appoints chief technology officer
- Spirit Health Group offers new market access consultancy service
- Why heading online for scientific meetings can yield greater HCP engagement
PMHub
StratX
StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...
Latest intelligence
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Quick links
Infographics
